🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines

Published 09/26/2024, 10:49 AM
Updated 09/26/2024, 11:12 AM
© Reuters. FILE PHOTO: Undated handout picture of a Bavarian Nordic research team member holding a test tube obtained by Reuters on August 16, 2024.   Bavarian Nordic/Mikkel Inumineq/Handout via REUTERS/File Photo
BAVA
-

(Reuters) -Bavarian Nordic said on Thursday it has signed an agreement with the United Nations Children's Fund (UNICEF) for one million doses of its mpox vaccine, Jynneos, for countries in Africa impacted by the disease outbreak.

The agreement includes 500,000 doses of the vaccine previously committed by Gavi, a public-private alliance that co-funds vaccine purchases for low-income countries.

© Reuters. FILE PHOTO: Undated handout picture of a Bavarian Nordic research team member holding a test tube obtained by Reuters on August 16, 2024.   Bavarian Nordic/Mikkel Inumineq/Handout via REUTERS/File Photo

The Danish biotech said it would make all doses available for supply before the end of this year and work with partners to secure the availability of vaccines beyond 2024.

This is the first award of vaccines under an emergency tender issued by UNICEF to secure mpox vaccines for crisis-hit countries in collaboration with the Gavi alliance, Africa CDC and the World Health Organization, the company said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.